Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Alopecia areata · Multiple myeloma

First Biotech (Australia)

Pfizer Australia Pty Ltd

First Biotech (Australia) drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU HQ
2017 Founded
2 Employees
TGA registrant Type
Company details
Status
Public
HQ
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
Founded
2017
Employees
2
Programs
126
Drugs
208
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

First Biotech (Australia) pipeline

Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

First Biotech (Australia) drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

200 compounds

  1. abemaciclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  2. abrocitinib

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.

    Target
    Tyrosine-protein kinase JAK1
    Mechanism
    Tyrosine-protein kinase JAK1 inhibitor

  3. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  4. alprostadil

    US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP1 subtype.

    Target
    Prostaglandin E2 receptor EP1 subtype
    Mechanism
    Prostanoid EP1 receptor agonist

  5. arginine

    Various (V03)

    Various (V03) compound in First Biotech (Australia)'s portfolio.

  6. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  7. avelumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 other

  8. axitinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.

    Target
    Vascular endothelial growth factor receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  9. azathioprine

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.

    Target
    Amidophosphoribosyltransferase
    Mechanism
    Amidophosphoribosyltransferase inhibitor

  10. azithromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  11. aztreonam

    Antiinfectives for systemic use (J01)

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  12. benzathine benzylpenicillin

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  13. betamethasone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  14. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  15. binimetinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

  16. bleomycin

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  17. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  18. budesonide

    Alimentary tract and metabolism (A07)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  19. cabergoline

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Dopamine D2 receptor agonist

  20. calcium

    US regulatory status: approved.

  21. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  22. capsule

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  23. capsules

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  24. carbamazepine

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  25. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  26. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  27. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  28. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  29. chlorhexidine gluconate

    US regulatory status: approved. Molecular target: Cell membrane.

    Target
    Cell membrane
    Mechanism
    Cell membrane inhibitor

  30. chloride

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  31. chloroquine phosphate

    US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.

    Target
    Ferriprotoporphyrin IX
    Mechanism
    Ferriprotoporphyrin IX inhibitor

  32. clarithromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  33. clindamycin

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  34. clobazam

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  35. control

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  36. cortisone

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  37. crisantaspase

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in First Biotech (Australia)'s portfolio. Molecular target: Asparagine.

    Target
    Asparagine
    Mechanism
    Asparagine hydrolytic enzyme

  38. crizotinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.

    Target
    ALK tyrosine kinase receptor
    Mechanism
    Hepatocyte growth factor receptor inhibitor

  39. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  40. cyclosporine

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.

    Target
    Peptidyl-prolyl cis-trans isomerase A
    Mechanism
    Cyclophilin A modulator

  41. cytarabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  42. dabigatran

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Prothrombin.

    Target
    Prothrombin
    Mechanism
    Thrombin inhibitor

  43. dabigatran etexilate

    Blood and blood forming organs (B01)

    Blood and blood forming organs (B01) compound in First Biotech (Australia)'s portfolio. Mechanism: Thrombin inhibitor.

    Mechanism
    Thrombin inhibitor

  44. dantrolene

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: Ryanodine receptor 3 antagonist.

    Mechanism
    Ryanodine receptor 3 antagonist

  45. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  46. deflazacort

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  47. desferrioxamine

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  48. desonide

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  49. desvenlafaxine

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  50. dexamethasone

    Systemic hormonal preparations (H02)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  51. dexamethasone phosphate

    Systemic hormonal preparations (H02)

    Systemic hormonal preparations (H02) compound in First Biotech (Australia)'s portfolio.

  52. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  53. diphenhydramine

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  54. diphenhydramine hydrochloride

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  55. disitamab

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  56. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  57. donepezil

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.

    Mechanism
    Acetylcholinesterase inhibitor

  58. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in First Biotech (Australia)'s portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  59. eculizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Complement C5.

    Target
    Complement C5
    Mechanism
    Complement C5 inhibitor

  60. elotuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: SLAM family member 7.

    Target
    SLAM family member 7
    Mechanism
    SLAM family member 7 inhibitor

  61. elranatamab

    US regulatory status: approved. Molecular target: T cell surface glycoprotein CD3.

    Target
    T cell surface glycoprotein CD3
    Mechanism
    T cell surface glycoprotein CD3 binding agent

  62. encorafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.

    Target
    Serine/threonine-protein kinase B-raf
    Mechanism
    Serine/threonine-protein kinase B-raf inhibitor

  63. enzalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  64. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  65. etanercept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  66. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  67. etrasimod

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in First Biotech (Australia)'s portfolio. Molecular target: Sphingosine 1-phosphate receptor 1.

    Target
    Sphingosine 1-phosphate receptor 1
    Mechanism
    Sphingosine 1-phosphate receptor Edg-6 modulator

  68. etrasimod arginine

    US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 1.

    Target
    Sphingosine 1-phosphate receptor 1
    Mechanism
    Sphingosine 1-phosphate receptor Edg-6 modulator

  69. everolimus

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  70. exemestane

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  71. fidanacogene elaparvovec

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Coagulation factor IX.

    Target
    Coagulation factor IX
    Mechanism
    Coagulation factor IX exogenous gene

  72. filgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  73. fluconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  74. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  75. folinic acid

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  76. formulation

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  77. fulvestrant

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor antagonist

  78. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  79. gemtuzumab ozogamicin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Myeloid cell surface antigen CD33 binding agent

  80. glipizide

    US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.

    Target
    Sulfonylurea receptor 1, Kir6.2
    Mechanism
    Sulfonylurea receptor 1, Kir6.2 blocker

  81. glofitamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in First Biotech (Australia)'s portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  82. glofitamab-gxbm

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  83. granule

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  84. granules

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  85. group

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  86. hema-

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  87. heparin

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III activator

  88. human normal immunoglobulin (ivig)

    Antiinfectives for systemic use (J06)

    Antiinfectives for systemic use (J06) compound in First Biotech (Australia)'s portfolio. Mechanism: Replacement therapy, immunomodulatory effects.

    Mechanism
    Replacement therapy, immunomodulatory effects

  89. hydrocortisone

    Systemic hormonal preparations (H02)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  90. hydrocortisone sodium succinate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  91. hydromorphone

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  92. hydroxocobalamin

    Various (V03)

    US regulatory status: approved. Molecular target: Cyanide.

    Target
    Cyanide
    Mechanism
    Cyanide sequestering agent

  93. hydroxychloroquine

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.

    Mechanism
    Toll-like receptor 7 antagonist

  94. idarubicin

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  95. infliximab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  96. infusion

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  97. injection

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  98. inotuzumab ozogamicin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-cell receptor CD22.

    Target
    B-cell receptor CD22
    Mechanism
    CD22 binding agent

  99. insulin lispro

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  100. intervention

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  101. intravenous

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  102. ipilimumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  103. irinotecan

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  104. irinotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  105. itraconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  106. lansoprazole

    US regulatory status: approved. Molecular target: Potassium-transporting ATPase.

    Target
    Potassium-transporting ATPase
    Mechanism
    Potassium-transporting ATPase inhibitor

  107. leflunomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydroorotate dehydrogenase (quinone), mitochondrial.

    Target
    Dihydroorotate dehydrogenase (quinone), mitochondrial
    Mechanism
    Dihydroorotate dehydrogenase inhibitor

  108. letrozole

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  110. lincomycin

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  111. liraglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  112. loratadine

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  113. lorlatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.

    Target
    ALK tyrosine kinase receptor
    Mechanism
    EML4-ALK inhibitor

  115. malathion

    US regulatory status: approved. Molecular target: Acetylcholinesterase.

    Target
    Acetylcholinesterase
    Mechanism
    Acetylcholinesterase inhibitor

  116. malignant

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  117. management

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  118. matching

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  119. medroxyprogesterone

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor agonist

  120. mefenamic acid

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  121. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  122. methylprednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  123. metronidazole

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  124. midazolam

    Nervous system (N05)

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  125. minoxidil

    US regulatory status: approved. Molecular target: Sulfonylurea receptor 2, Kir6.2.

    Target
    Sulfonylurea receptor 2, Kir6.2
    Mechanism
    Sulfonylurea receptor 2, Kir6.2 opener

  126. mitoxantrone hydrochloride

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA topoisomerase II alpha inhibitor

  127. mycophenolate

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).

    Target
    Inosine-5'-monophosphate dehydrogenase (IMPDH)
    Mechanism
    Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor

  128. mycophenolate mofetil

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).

    Target
    Inosine-5'-monophosphate dehydrogenase (IMPDH)
    Mechanism
    Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor

  129. nafarelin

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: Gonadotropin-releasing hormone receptor agonist.

    Mechanism
    Gonadotropin-releasing hormone receptor agonist

  130. naloxone

    Various (V03)

    Various (V03) compound in First Biotech (Australia)'s portfolio. Mechanism: Opioid receptors; mu/kappa/delta antagonist.

    Mechanism
    Opioid receptors; mu/kappa/delta antagonist

  131. nirmatrelvir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Replicase polyprotein 1a.

    Target
    Replicase polyprotein 1a
    Mechanism
    SARS coronavirus 3C-like proteinase inhibitor

  132. nivolumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  133. norethisterone

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor agonist

  135. obinutuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  136. omacetaxine mepesuccinate

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Mechanism: Protein synthesis inhibitor.

    Mechanism
    Protein synthesis inhibitor

  137. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  138. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  139. palbociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: CDK6/cyclin D1.

    Target
    CDK6/cyclin D1
    Mechanism
    Cyclin-dependent kinase 4/cyclin D1 inhibitor

  140. pamidronate disodium

    US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.

    Target
    Farnesyl pyrophosphate synthase
    Mechanism
    Farnesyl diphosphate synthase inhibitor

  141. pantoprazole

    Alimentary tract and metabolism (A02)

    Alimentary tract and metabolism (A02) compound in First Biotech (Australia)'s portfolio. Mechanism: Potassium-transporting ATPase inhibitor.

    Mechanism
    Potassium-transporting ATPase inhibitor

  142. pantoprazole sodium

    US regulatory status: approved. Molecular target: Potassium-transporting ATPase.

    Target
    Potassium-transporting ATPase
    Mechanism
    Potassium-transporting ATPase inhibitor

  143. pegaspargase

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Asparagine.

    Target
    Asparagine
    Mechanism
    Asparagine hydrolytic enzyme

  144. pegvisomant

    Systemic hormonal preparations (H01)

    US regulatory status: approved. Molecular target: Growth hormone receptor.

    Target
    Growth hormone receptor
    Mechanism
    Growth hormone receptor antagonist

  145. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  146. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  147. placebo

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  148. pneumococcal

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  150. polidocanol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  151. polysaccharide

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  152. powder

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  153. prazosin

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Mechanism: Adrenergic receptor alpha-1 antagonist.

    Mechanism
    Adrenergic receptor alpha-1 antagonist

  154. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  155. prednisone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  156. progression

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  157. protocol

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  158. raltitrexed

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Thymidylate synthase.

    Target
    Thymidylate synthase
    Mechanism
    Thymidylate synthase inhibitor

  159. reboxetine

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  160. recombinant

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  161. remdesivir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: RNA-directed RNA polymerase L.

    Target
    RNA-directed RNA polymerase L
    Mechanism
    RNA-directed RNA polymerase L inhibitor

  162. respiratory syncytial virus vaccine (bivalent, recombinant)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in First Biotech (Australia)'s portfolio. Molecular target: Fusion glycoprotein F0.

    Target
    Fusion glycoprotein F0
    Mechanism
    Fusion glycoprotein F0 vaccine antigen

  163. ribociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  164. rifabutin

    US regulatory status: approved. Molecular target: Bacterial DNA-directed RNA polymerase.

    Target
    Bacterial DNA-directed RNA polymerase
    Mechanism
    Bacterial DNA-directed RNA polymerase inhibitor

  165. rimegepant

    Nervous system (N02)

    US regulatory status: approved. Molecular target: Calcitonin gene-related peptide type 1 receptor.

    Target
    Calcitonin gene-related peptide type 1 receptor
    Mechanism
    Calcitonin gene-related peptide type 1 receptor antagonist

  166. rimegepant sulfate

    US regulatory status: approved. Molecular target: Calcitonin gene-related peptide type 1 receptor.

    Target
    Calcitonin gene-related peptide type 1 receptor
    Mechanism
    Calcitonin gene-related peptide type 1 receptor antagonist

  167. ritlecitinib

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in First Biotech (Australia)'s portfolio. Molecular target: TEC family kinase.

    Target
    TEC family kinase
    Mechanism
    Tyrosine-protein kinase JAK3 inhibitor

  168. ritlecitinib tosilate

    Development asset linked to First Biotech (Australia) in public FDA and regional records. Molecular target: TEC family kinase.

    Target
    TEC family kinase
    Mechanism
    TEC family kinase inhibitor

  169. ritonavir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Cytochrome P450 3A.

    Target
    Cytochrome P450 3A
    Mechanism
    Cytochrome P450 3A inhibitor

  170. rituximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  171. saline

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  172. sars-cov-

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  173. sasanlimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in First Biotech (Australia)'s portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 antagonist

  174. sirolimus

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  176. solution

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  177. solvent

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  178. somatrogon

    Systemic hormonal preparations (H01)

    Systemic hormonal preparations (H01) compound in First Biotech (Australia)'s portfolio. Molecular target: Growth hormone receptor.

    Target
    Growth hormone receptor
    Mechanism
    Growth hormone receptor agonist

  179. somatropin

    Systemic hormonal preparations (H01)

    US regulatory status: approved. Molecular target: Growth hormone receptor.

    Target
    Growth hormone receptor
    Mechanism
    Growth hormone receptor agonist

  180. spironolactone

    Cardiovascular system (C03)

    US regulatory status: approved. Molecular target: Mineralocorticoid receptor.

    Target
    Mineralocorticoid receptor
    Mechanism
    Mineralocorticoid receptor antagonist

  181. stro-

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  182. sulfasalazine

    US regulatory status: approved. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.

    Target
    Polyunsaturated fatty acid 5-lipoxygenase
    Mechanism
    Arachidonate 5-lipoxygenase inhibitor

  183. sunitinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in First Biotech (Australia)'s portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.

    Target
    Macrophage colony-stimulating factor 1 receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  184. suspension

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  185. t-cell

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  186. tablet

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  187. tablets

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  188. tafamidis

    Nervous system (N07)

    US regulatory status: approved. Molecular target: Transthyretin.

    Target
    Transthyretin
    Mechanism
    Transthyretin stabiliser

  189. talazoparib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in First Biotech (Australia)'s portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.

    Target
    Poly [ADP-ribose] polymerase 2
    Mechanism
    Poly [ADP-ribose] polymerase 2 inhibitor

  190. temozolomide

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  191. ticarcillin disodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  192. tobramycin

    Antiinfectives for systemic use (J01)

    US regulatory status: approved. Molecular target: 70S ribosome.

    Target
    70S ribosome
    Mechanism
    70S ribosome inhibitor

  193. tofacitinib

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Mechanism: Janus Kinase (JAK) inhibitor.

    Mechanism
    Janus Kinase (JAK) inhibitor

  194. tofacitinib citrate

    US regulatory status: approved. Molecular target: Janus Kinase (JAK).

    Target
    Janus Kinase (JAK)
    Mechanism
    Janus Kinase (JAK) inhibitor

  195. topotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  196. tranexamic acid

    US regulatory status: approved. Molecular target: Plasminogen.

    Target
    Plasminogen
    Mechanism
    Plasminogen inhibitor

  197. trastuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  198. treatment

    Development asset linked to First Biotech (Australia) in public FDA and regional records.

  199. tretinoin

    US regulatory status: approved. Molecular target: Retinoic acid receptor.

    Target
    Retinoic acid receptor
    Mechanism
    Retinoic acid receptor agonist

  200. triamcinolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.